Toluene

Toluene

SCHEMBL249049

CC(=O)Cc1ccc(C)cc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.58
TDP1 Q9NUW8 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.52
CTBP2 P56545 1/20 0.52
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
CNR1 P21554 1/20 0.49
CNR2 P34972 1/20 0.49
LMNA P02545 3/20 0.47
POLB P06746 1/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
CES2 O00748 2/20 0.47
CES1 P23141 2/20 0.47
AKR1B1 P15121 1/20 0.46
PSMB8 P28062 1/20 0.46
PSMB5 P28074 1/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.46
TSHR P16473 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL249116 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL1076401 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL9462510 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL6422812 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL9293975 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL249639 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL2053140 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL1118344 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL3869236 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A
Toluene SCHEMBL1143384 1.00 L3MBTL1 (0.58) L3MBTL1TDP1SMN1; SMN2CTBP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
CN-100575345-C 2 type Cannabined receptors are had in conjunction with active Pyridione derivatives SHIONOGI & CO 2009-12-30 CN disclosed
EP-2130820-A1 Antipruritics SHIONOGI & CO., LTD. (JP) 2009-12-09 EP disclosed
EP-1477186-B1 ANTIPRURITICS SHIONOGI & CO (JP) 2009-11-11 EP disclosed
EP-1357111-B1 2-PYRIDONE DERIVATIVES HAVING AFFINITY FOR CANNABINOID TYPE 2 RECEPTOR SHIONOGI & CO (JP) 2009-08-05 EP disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed
US-20060052411-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor TADA YUKIO 2006-03-09 US disclosed
US-6977266-B2 Pyridone derivatives having affinity for cannabinoid 2-type receptor SHIONOGI & CO., LTD. (JP) 2005-12-20 US disclosed
US-20050101590-A1 Cannabinoid receptor agonists SHIONOGI & CO., LTD. (JP) 2005-05-12 US disclosed
EP-1477186-A1 ANTIPRURITICS SHIONOGI & CO., LTD. (JP) 2004-11-17 EP disclosed
US-20040082619-A1 Pyridone derivatives having affinity for cannabinoid 2-type receptor SHIONOGI & CO., LTD. (JP) 2004-04-29 US disclosed
CN-1492856-A Pyridone derivative having affinity for cannabinoid 2-type receptor ��Ұ����ҩ��ʽ���� 2004-04-28 CN disclosed
EP-1357111-A1 PYRIDONE DERIVATIVE HAVING AFFINITY FOR CANNABINOID 2-TYPE RECEPTOR SHIONOGI & CO., LTD. (JP) 2003-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R L3MBTL1 4225/4885TDP1 4271/4885SMN1; SMN2 4652/4885
US-20050101590-A1 Cannabinoid receptor agonists CNR1, CNR2, OPRL1 L3MBTL1 3887/4885TDP1 4762/4885SMN1; SMN2 3763/4885
US-20060052411-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor CNR2, CNR1, NPY2R L3MBTL1 3979/4885TDP1 3664/4885SMN1; SMN2 4681/4885
US-20080312292-A1 Antipruritics CNR1, CNR2, OPRL1 L3MBTL1 3630/4885TDP1 4657/4885SMN1; SMN2 3366/4885
US-20040082619-A1 Pyridone derivatives having affinity for cannabinoid 2-type receptor CNR1, CNR2, NPY1R L3MBTL1 3450/4885TDP1 3425/4885SMN1; SMN2 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.